Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 41 peer-reviewed journal articles Updated
Urology · Persistently Elevated Prostate-Specific Antigen (PSA)

What to Do After a Negative Prostate Biopsy With High PSA?

At a Glance

A negative prostate biopsy means no cancer was found in the sampled tissue, but it cannot completely rule out a missed tumor. If PSA stays elevated, doctors reassess the PSA trend, prostate size, biopsy findings, and other risk factors, then use MRI to choose monitoring or repeat biopsy.

In this answer

6 sections

01

Confirm the PSA Trend and Your Full Risk Picture

02

Reassess Prostate Volume and PSA Density

03

Review the Previous Biopsy and Pathology

04

Get a High-Quality mpMRI

05

Consider Biomarker Tests

06

Discussing the Next Step: Structured Follow-Up or Repeat Biopsy

A negative prostate biopsy brings initial relief, but facing continued uncertainty because your prostate-specific antigen (PSA)—a protein produced by both normal and cancerous prostate cells—remains high can be stressful. A persistently elevated PSA after a negative biopsy does not automatically mean you have cancer, nor does it guarantee you are clear [1]. Instead, it requires a careful reassessment of your total risk [2]. Your medical team will typically confirm your PSA trend, review other risk factors, calculate your PSA density, re-evaluate your previous biopsy, and use a multiparametric MRI (mpMRI) before deciding whether a repeat biopsy or structured follow-up is best [2][3].

Confirm the PSA Trend and Your Full Risk Picture

PSA values can fluctuate. Decisions are never based on a single PSA number but on a combination of factors, including your PSA trend, age, ancestry, family history, and physical examination (such as a digital rectal exam or DRE) [4][5]. Your doctor will first want to confirm the PSA under stable conditions.

  • Wait for the prostate to recover: Procedures like your recent prostate biopsy, catheterization, or a cystoscopy can transiently raise your PSA for several weeks [6][7]. Your clinician will direct the right timing for a repeat test.
  • Resolve infections first: Active urinary tract infections (UTIs) or urinary retention also spike PSA [8][9]. PSA testing should occur after these issues have fully resolved. However, antibiotics should not be taken routinely just to lower an unexplained high PSA if there is no evidence of a bacterial infection [10][11].
  • Check for benign prostate conditions: Benign prostatic hyperplasia (BPH) (a non-cancerous enlargement of the prostate) and prostatitis (prostate inflammation) commonly elevate PSA [8]. Inflammation noted on your previous biopsy might help explain the elevation [12].
  • Review your medications: If you take a 5-alpha-reductase inhibitor (like finasteride or dutasteride) for BPH, it artificially lowers your PSA [13]. A confirmed rise or a failure of the PSA to fall as expected while on these drugs warrants clinical review, as your doctor must adjust your baseline values [13].

Reassess Prostate Volume and PSA Density

A larger prostate naturally produces more PSA. To help distinguish between BPH and cancer risk, doctors use PSA density [2].

  • PSA density is your PSA level divided by your prostate volume (measured in ng/mL per cc or cm³) [2].
  • A lower PSA density suggests the elevation may be driven by an enlarged prostate, while a higher PSA density increases the suspicion of cancer [14][15].
  • There is no universal “safe” cutoff [16]. While a low PSA density lowers your risk, it does not completely eliminate the possibility of cancer [14]. Prostate volume (measured by MRI or ultrasound) is combined with your other risk factors to guide decisions [17].

Review the Previous Biopsy and Pathology

A negative biopsy means no cancer was found in the specific tissues sampled, but needle biopsies can occasionally miss a tumor, especially depending on how the procedure was performed [3].

  • Biopsy method and coverage: Your doctor will review whether your previous biopsy was transrectal (through the rectum) or transperineal (through the skin). Transrectal biopsies sometimes miss tumors located in the anterior (front) zone of the prostate [18]. They will also check if enough cores (samples) were taken [19].
  • Atypical pathology findings: Even if the result was “negative” for cancer, the pathologist may have seen atypical cells [20].
    • Atypical Small Acinar Proliferation (ASAP): This is a suspicious finding that is not definitively cancer, but its presence commonly leads to consideration for a repeat biopsy [21].
    • High-Grade Prostatic Intraepithelial Neoplasia (HGPIN): These are abnormal cells, but they are not cancer. Finding isolated or focal HGPIN on a modern biopsy does not automatically require an immediate repeat biopsy [22]. Management depends on whether it is extensive and on your other risk factors [23].

Get a High-Quality mpMRI

If you have not had one recently, a high-quality multiparametric MRI (mpMRI) is usually the pivotal next step [24][3]. An MRI highlights specific suspicious areas, graded on the PI-RADS (Prostate Imaging Reporting and Data System) scale from 1 (very low suspicion) to 5 (very high suspicion) [25].

  • PI-RADS 4 or 5: These are highly suspicious for clinically significant cancer and usually strongly warrant an MRI-targeted repeat biopsy [3][26].
  • PI-RADS 3: This is an equivocal (indeterminate) result. The decision to biopsy depends heavily on your PSA density, family history, and other clinical factors [27][16].
  • PI-RADS 1 or 2: A negative MRI lowers, but does not completely eliminate, the risk of clinically significant cancer [28]. Depending on your PSA density and exam, you and your doctor may choose structured follow-up instead of immediate biopsy [28][29].

Consider Biomarker Tests

If your MRI and clinical risk leave uncertainty about whether to do a repeat biopsy, specialized biomarker tests may act as a tiebreaker [30].

  • Blood and Urine Tests: Tests like the Prostate Health Index (PHI), 4Kscore, ExoDx, and SelectMDx are risk-stratification tools [31][32][33]. They help estimate the probability of finding a high-grade cancer.
  • Tissue Tests: ConfirmMDx can be run on the tissue from your previous negative biopsy to look for genetic markers (methylation) suggestive of nearby cancer [34].
  • Important Limitations: These are not diagnostic tests—they cannot definitively confirm or rule out cancer [35]. They can have false positives and false negatives, and they may not be covered by all insurance plans. They are most useful when their result will actually change your decision to have a biopsy [35][36].

Discussing the Next Step: Structured Follow-Up or Repeat Biopsy

After weighing your MRI, PSA density, biomarkers, and clinical exam, you will discuss whether to actively monitor your condition or proceed with another biopsy [36].

Option 1: Structured Follow-Up

If your risk is deemed low (e.g., negative MRI and low PSA density), you might opt for structured follow-up rather than a biopsy [28]. This involves a set schedule to recheck your PSA and digital rectal exam, and explicit triggers (such as a rapidly rising PSA) that would prompt a new MRI or biopsy [37].

Option 2: Repeat Biopsy

If suspicion remains high, a repeat biopsy is considered [3]. Extensive “saturation” sampling (taking many extra cores) is a selective option for persistent high suspicion, but it is not routine because it can increase complication risks [38]. No biopsy guarantees finding every tumor [38].

Biopsy Approach How It Works Trade-offs & Notes
MRI-Targeted Needles are guided directly into PI-RADS suspicious areas [3]. Highly effective at finding significant cancers, but might miss tumors outside the target [25].
Systematic Standard template of 10-12 cores taken across the prostate [19]. Often combined with targeted cores to maximize detection [39].
Transrectal Probe and needles go through the rectum [40]. Can sometimes miss anterior (front) tumors. Higher risk of serious infection [18][41].
Transperineal Needles go through the skin between scrotum and anus [18]. Better access to the anterior prostate. Generally lower infection risk, but may cause more temporary swelling or discomfort [18][41].

Biopsy Risks and When to Seek Help
All biopsies carry risks, including soreness and seeing blood in your urine, stool, or semen for several weeks. Other risks include urinary retention (inability to pee) and infection [41]. Seek immediate urgent medical care if you experience a fever, chills, heavy or persistent bleeding, or if you cannot urinate.

Common questions in this guide

Can prostate cancer still be present after a negative biopsy if my PSA stays high?
Yes. A negative biopsy means cancer was not found in the tissue samples collected, but a biopsy can miss a tumor, particularly if some areas of the prostate were not adequately sampled. Persistent PSA elevation should be evaluated using your full risk picture rather than treated as proof that cancer is present or absent.
What can cause a high PSA after a negative prostate biopsy?
A recent biopsy, catheterization, cystoscopy, urinary infection, urinary retention, prostatitis, or benign prostate enlargement can raise PSA. Medicines such as finasteride and dutasteride lower PSA and change how the result is interpreted. Antibiotics should not be used only to lower an unexplained PSA unless there is evidence of a bacterial infection.
When should PSA be checked again after a biopsy or infection?
PSA is generally rechecked after the prostate has had time to recover from a biopsy or other procedure and after a urinary infection or retention has resolved. The appropriate interval depends on what happened and your clinician’s instructions, so there is no single timing that fits everyone.
What is PSA density, and why does it matter after a negative biopsy?
PSA density is the PSA level divided by prostate volume, which can be measured with MRI or ultrasound. A lower value may support benign enlargement as an explanation, while a higher value increases concern, but no cutoff completely rules prostate cancer in or out.
What does a prostate MRI show after a negative biopsy?
A multiparametric MRI identifies areas that may need targeted sampling and rates them from PI-RADS 1 to 5. PI-RADS 4 or 5 usually supports a targeted repeat biopsy; PI-RADS 3 requires individualized assessment, and PI-RADS 1 or 2 lowers but does not eliminate the risk of clinically significant cancer.
Can a biomarker test tell me whether I need another prostate biopsy?
Blood, urine, or tissue tests such as PHI, 4Kscore, ExoDx, SelectMDx, and ConfirmMDx can help estimate the chance of finding high-grade cancer when MRI and other findings are uncertain. They do not diagnose or rule out cancer and are most useful when the result would change the decision about another biopsy.
What type of repeat prostate biopsy might be recommended?
A repeat biopsy may combine MRI-targeted cores with systematic sampling when suspicion remains high. Transperineal biopsy may provide better access to the front of the prostate and generally has a lower serious infection risk than transrectal biopsy, but the best approach depends on your MRI findings, prior sampling, and overall risk.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Related questions

What Do PI-RADS 3, 4, and 5 Mean on a Prostate MRI? How Long Is ADT With Radiation for Prostate Cancer? What Is the Next Step After a High PSA? Testing Path When Is PSMA PET/CT Needed for Prostate Cancer Staging? How Are the Six Prostate Cancer Risk Groups Defined?
Show more
Can Prostatitis, BPH, Sex, or Cycling Raise PSA Levels? Can You Have Prostate Cancer With a Negative MRI, High PSA? How Do Cribriform and IDC-P Affect Prostate Cancer Risk? Surgery or Radiation Better for High-Risk Prostate Cancer? How Often Is Low-Risk Prostate Cancer Actively Monitored? Can a Second Review Change Your Prostate Cancer Grade? What Do T, N, and M Stages Mean in Prostate Cancer? Should I Get Genetic Testing After Prostate Cancer? How Do Age and Health Affect Prostate Cancer Treatment? When to Leave Active Surveillance for Prostate Cancer? Are Genomic Tests Useful for Prostate Cancer Decisions? Can Testosterone or Supplements Worsen Prostate Cancer? Why Are Prostate Biopsies Done? Risks and Methods Explained When Should I Start Prostate Cancer Screening If High Risk?

Get notified when new evidence is published on prostate adenocarcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my exact PSA density, and how does it influence my risk alongside my family history and digital rectal exam?
  2. 2.Did the pathology report from my first biopsy show ASAP, extensive HGPIN, or signs of inflammation?
  3. 3.Did my previous biopsy adequately sample the anterior (front) zone of my prostate?
  4. 4.How long should we wait after my recent biopsy (or recent infection) before rechecking my PSA?
  5. 5.Would you recommend a multiparametric MRI to assess my current risk? If my MRI is negative (PI-RADS 1 or 2) or indeterminate (PI-RADS 3), what specific triggers would prompt a biopsy?
  6. 6.If we proceed with a repeat biopsy, would a targeted, combined, or transperineal approach be best for my specific situation?

References

References (41)
  1. 1

    Prostate-specific antigen kinetics contributes to decision making for biopsy referral: the predictive implication for PSA retest in patients with elevated PSA levels.

    Kobayashi M, Kijima T, Yashi M, Kamai T

    Prostate international 2023; (11(1)):27-33 doi:10.1016/j.prnil.2022.08.001.

    PMID: 36910897
  2. 2

    Implications of the European Association of Urology Recommended Risk Assessment Algorithm for Early Prostate Cancer Detection.

    Israël B, Hannink G, Barentsz JO, van der Leest MMG

    European urology open science 2022; (43()):1-4 doi:10.1016/j.euros.2022.06.006.

    PMID: 35845549
  3. 3

    Prostate Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Patients with a Prior Negative Biopsy: A Consensus Statement by AUA and SAR.

    Rosenkrantz AB, Verma S, Choyke P, et al.

    The Journal of urology 2016; (196(6)):1613-1618 doi:10.1016/j.juro.2016.06.079.

    PMID: 27320841
  4. 4

    Prostate Specific Antigen Density as a Predictor of Clinically Significant Prostate Cancer When the Prostate Specific Antigen is in the Diagnostic Gray Zone: Defining the Optimum Cutoff Point Stratified by Race and Body Mass Index.

    Aminsharifi A, Howard L, Wu Y, et al.

    The Journal of urology 2018; (200(4)):758-766 doi:10.1016/j.juro.2018.05.016.

    PMID: 29758219
  5. 5

    Use of Digital Rectal Examination as an Adjunct to Prostate Specific Antigen in the Detection of Clinically Significant Prostate Cancer.

    Halpern JA, Oromendia C, Shoag JE, et al.

    The Journal of urology 2018; (199(4)):947-953 doi:10.1016/j.juro.2017.10.021.

    PMID: 29061540
  6. 6

    [Preoperative PSA levels and development of PSA after 180-W XPS greenlight laser treatment of the prostate: what is the reality in clinical routine practice?]

    Wiedemann A, Heese M, Heppner HJ

    Aktuelle Urologie 2020; (51(1)):53-58 doi:10.1055/a-1021-6776.

    PMID: 32018334
  7. 7

    Prospective investigation of change in the prostate-specific antigens after various urologic procedures.

    Park SC, Shin YS, Zhang LT, et al.

    Clinical interventions in aging 2015; (10()):1213-8 doi:10.2147/CIA.S84570.

    PMID: 26251583
  8. 8

    For Physicians Managing Voiding Dysfunction, Improving the Detection Rate of Early Prostate Cancer and Discrimination From Benign Prostatic Hyperplasia, in a Molecular Biomarker Aspects.

    Kim WT, Yun SJ, Kim WJ

    International neurourology journal 2019; (23(1)):5-12 doi:10.5213/inj.1836262.131.

    PMID: 30943689
  9. 9

    The Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer Screening.

    Vickers AJ, Eastham JA, Scardino PT, Lilja H

    Urology 2016; (91()):12-8.

    PMID: 26850815
  10. 10

    Do antibiotics decrease prostate-specific antigen levels and reduce the need for prostate biopsy in type IV prostatitis? A systematic literature review.

    Buddingh KT, Maatje MGF, Putter H, et al.

    Canadian Urological Association journal = Journal de l'Association des urologues du Canada 2018; (12(1)):E25-E30 doi:10.5489/cuaj.4515.

    PMID: 29173276
  11. 11

    Six Weeks of Fluoroquinolone Antibiotic Therapy for Patients With Elevated Serum Prostate-specific Antigen Is Not Clinically Beneficial: A Randomized Controlled Clinical Trial.

    Greiman A, Shah J, Bhavsar R, et al.

    Urology 2016; (90()):32-7.

    PMID: 26802800
  12. 12

    Greater extent of prostate inflammation in negative biopsies is associated with lower risk of prostate cancer on repeat biopsy: results from the REDUCE study.

    Moreira DM, Nickel JC, Andriole GL, et al.

    Prostate cancer and prostatic diseases 2016; (19(2)):180-4 doi:10.1038/pcan.2015.66.

    PMID: 26782712
  13. 13

    Prostate-Specific Antigen Kinetics Following 5α-Reductase Inhibitor Treatment May Be a Useful Indicator for Repeat Prostate Biopsy.

    Heo JE, Koo KC, Hong SJ, et al.

    Yonsei medical journal 2018; (59(2)):219-225 doi:10.3349/ymj.2018.59.2.219.

    PMID: 29436189
  14. 14

    Re-examining Prostate-specific Antigen (PSA) Density: Defining the Optimal PSA Range and Patients for Using PSA Density to Predict Prostate Cancer Using Extended Template Biopsy.

    Jue JS, Barboza MP, Prakash NS, et al.

    Urology 2017; (105()):123-128 doi:10.1016/j.urology.2017.04.015.

    PMID: 28431993
  15. 15

    Predictors for the detection of prostate cancer and clinically significant prostate cancer using TRUS-guided biopsy in patients with negative initial biopsy results.

    Yoo S, Park J, Cho SY, et al.

    World journal of urology 2018; (36(7)):1047-1053 doi:10.1007/s00345-018-2239-1.

    PMID: 29497858
  16. 16

    Prediction of Significant Prostate Cancer in Equivocal Magnetic Resonance Imaging Lesions: A High-volume International Multicenter Study.

    Sigle A, Borkowetz A, von Hardenberg J, et al.

    European urology focus 2023; (9(4)):606-613 doi:10.1016/j.euf.2023.01.020.

    PMID: 36804191
  17. 17

    Indications for a second prostate biopsy in patients suspected with prostate cancer after an initial negative prostate biopsy.

    Lee KS, Koo KC, Cho KS, et al.

    Prostate international 2017; (5(1)):24-28 doi:10.1016/j.prnil.2016.12.002.

    PMID: 28352620
  18. 18

    Transperineal biopsy prostate cancer detection in first biopsy and repeat biopsy after negative transrectal ultrasound-guided biopsy: the Victorian Transperineal Biopsy Collaboration experience.

    Ong WL, Weerakoon M, Huang S, et al.

    BJU international 2015; (116(4)):568-76 doi:10.1111/bju.13031.

    PMID: 25560926
  19. 19

    Advances in Prostate Biopsy.

    Egan Kelly JM, Mian BM

    The Urologic clinics of North America 2026; (53(1)):33-44 doi:10.1016/j.ucl.2025.09.002.

    PMID: 41266000
  20. 20

    Impact of the Pathologist on Prostate Biopsy Diagnosis and Immunohistochemical Stain Usage Within a Single Institution.

    Shah MD, Parwani AV, Zynger DL

    American journal of clinical pathology 2017; (148(6)):494-501 doi:10.1093/ajcp/aqx103.

    PMID: 29165567
  21. 21

    Atypical small acinar proliferation (ASAP): Is a repeat biopsy necessary ASAP? A multi-institutional review.

    Leone A, Gershman B, Rotker K, et al.

    Prostate cancer and prostatic diseases 2016; (19(1)):68-71 doi:10.1038/pcan.2015.52.

    PMID: 26857145
  22. 22

    The current recommendation for the management of isolated high-grade prostatic intraepithelial neoplasia.

    Morote J, Schwartzmann I, Celma A, et al.

    BJU international 2022; (129(5)):627-633 doi:10.1111/bju.15568.

    PMID: 34375498
  23. 23

    Clinical significance of the De Ritis ratio for detecting prostate cancer in a repeat prostate biopsy.

    Ha H, Chung JW, Ha YS, et al.

    Investigative and clinical urology 2019; (60(6)):447-453 doi:10.4111/icu.2019.60.6.447.

    PMID: 31692969
  24. 24

    PI-RADS Steering Committee: The PI-RADS Multiparametric MRI and MRI-directed Biopsy Pathway.

    Padhani AR, Barentsz J, Villeirs G, et al.

    Radiology 2019; (292(2)):464-474 doi:10.1148/radiol.2019182946.

    PMID: 31184561
  25. 25

    Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound image-fusion guided transperineal prostate biopsy in patients with a previous negative biopsy.

    Hansen NL, Kesch C, Barrett T, et al.

    BJU international 2017; (120(5)):631-638 doi:10.1111/bju.13711.

    PMID: 27862869
  26. 26

    Prostate Cancer Detection Percentages of Repeat Biopsy in Patients with Positive Multiparametric Magnetic Resonance Imaging (Prostate Imaging Reporting and Data System/Likert 3-5) and Negative Initial Biopsy. A Mini Systematic Review.

    Grivas N, Lardas M, Espinós EL, et al.

    European urology 2022; (82(5)):452-457 doi:10.1016/j.eururo.2022.07.025.

    PMID: 35985901
  27. 27

    Risk of prostate cancer for men with prior negative biopsies undergoing magnetic resonance imaging compared with biopsy-naive men: A prospective evaluation of the PLUM cohort.

    Patel HD, Koehne EL, Shea SM, et al.

    Cancer 2022; (128(1)):75-84 doi:10.1002/cncr.33875.

    PMID: 34427930
  28. 28

    Management of Patients With a Negative Multiparametric Prostate MRI Examination: AJR Expert Panel Narrative Review.

    Tan N, Pollock JR, Margolis DJA, et al.

    AJR. American journal of roentgenology 2024; (223(2)):e2329969 doi:10.2214/AJR.23.29969.

    PMID: 37877601
  29. 29

    Detection of prostate cancer using prostate imaging reporting and data system score and prostate-specific antigen density in biopsy-naive and prior biopsy-negative patients.

    Ryoo H, Kang MY, Sung HH, et al.

    Prostate international 2020; (8(3)):125-129 doi:10.1016/j.prnil.2020.03.003.

    PMID: 33102394
  30. 30

    Biomarkers for Prostate Biopsy and Risk Stratification of Newly Diagnosed Prostate Cancer Patients.

    Loeb S

    Urology practice 2017; (4(4)):315-321 doi:10.1016/j.urpr.2016.08.001.

    PMID: 29104903
  31. 31

    Finding the Wolf in Sheep's Clothing: The 4Kscore Is a Novel Blood Test That Can Accurately Identify the Risk of Aggressive Prostate Cancer.

    Punnen S, Pavan N, Parekh DJ

    Reviews in urology 2015; (17(1)):3-13.

    PMID: 26028995
  32. 32

    The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 years.

    Boegemann M, Stephan C, Cammann H, et al.

    BJU international 2016; (117(1)):72-9 doi:10.1111/bju.13139.

    PMID: 25818705
  33. 33

    A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Cancer in men with prior negative prostate biopsy undergoing repeat biopsy.

    McKiernan J, Noerholm M, Tadigotla V, et al.

    BMC urology 2020; (20(1)):138 doi:10.1186/s12894-020-00712-4.

    PMID: 32873277
  34. 34

    The role of prostate cancer biomarkers in undiagnosed men.

    Dani H, Loeb S

    Current opinion in urology 2017; (27(3)):210-216 doi:10.1097/MOU.0000000000000384.

    PMID: 28212119
  35. 35

    Utility of serum biomarkers for predicting cancer in patients with previous negative prostate biopsy.

    Wang Z, Chan MT, Tsang WC, Chiong E

    World journal of urology 2022; (40(9)):2255-2260 doi:10.1007/s00345-022-04085-1.

    PMID: 35821266
  36. 36

    Prostate Extracellular Vesicles and Prognostic Biomarkers of Clinically Significant Prostate Cancer: A Prospective Single-Institution Pilot Study.

    Britton CJ, Andrews JR, Arafa A, et al.

    The Prostate 2025; (85(6)):594-602 doi:10.1002/pros.24861.

    PMID: 39980247
  37. 37

    Diagnostic Performance of Prostate-specific Antigen Density for Detecting Clinically Significant Prostate Cancer in the Era of Magnetic Resonance Imaging: A Systematic Review and Meta-analysis.

    Wang S, Kozarek J, Russell R, et al.

    European urology oncology 2024; (7(2)):189-203 doi:10.1016/j.euo.2023.08.002.

    PMID: 37640584
  38. 38

    Is it Time to Perform Only Magnetic Resonance Imaging Targeted Cores? Our Experience with 1,032 Men Who Underwent Prostate Biopsy.

    Pepe P, Garufi A, Priolo GD, et al.

    The Journal of urology 2018; (200(4)):774-778 doi:10.1016/j.juro.2018.04.061.

    PMID: 29679618
  39. 39

    Fusion prostate biopsy outperforms 12-core systematic prostate biopsy in patients with prior negative systematic biopsy: A multi-institutional analysis.

    Sidana A, Watson MJ, George AK, et al.

    Urologic oncology 2018; (36(7)):341.e1-341.e7 doi:10.1016/j.urolonc.2018.04.002.

    PMID: 29753548
  40. 40

    Clinically Significant Prostate Cancer Detection Following Transrectal and Transperineal Biopsy: Results of the Prostate Biopsy Efficacy and Complications Randomized Clinical Trial.

    Mian BM, Feustel PJ, Aziz A, et al.

    The Journal of urology 2024; (212(1)):21-31 doi:10.1097/JU.0000000000003979.

    PMID: 38700844
  41. 41

    Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.

    Mian BM, Feustel PJ, Aziz A, et al.

    The Journal of urology 2024; (211(2)):205-213 doi:10.1097/JU.0000000000003788.

    PMID: 37976319

This page is for informational purposes only and does not constitute medical advice. Your urologist should interpret your PSA trend, MRI, pathology, and biopsy options in the context of your health.